Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHL TelemedicineSHMLF 51 Cash-to-Debt is 1.93 as of Dec. 2025, which is 124% above its 10-year median of 0.86. GuruFocus rates SHMLF with a GF Score™ of 51/100 and a GF Value™ of $11.86. The stock has 5 warning signs investors should review. Among 663 Healthcare Providers & Services companies, SHL Telemedicine ranks better than 65.61% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. SHL Telemedicine's cash to debt ratio for the quarter that ended in Dec. 2025 was 1.93.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, SHL Telemedicinecould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for SHL Telemedicine's Cash-to-Debt or its related term are showing as below:
SHMLF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.45 Med: 0.86 Max: 9.5
Current: 1.93
During the past 13 years, SHL Telemedicine's highest Cash to Debt Ratio was 9.50. The lowest was 0.45. And the median was 0.86.
SHMLF's Cash-to-Debt is ranked better than 65.61% of 663
companies
in the Healthcare Providers & Services industry
Industry Median: 0.77
vs SHMLF: 1.93
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
SHL Telemedicine Cash-to-Debt Related Terms
SHL Telemedicine Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for SHL Telemedicine's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Health Information Services subindustry, SHL Telemedicine's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SHL Telemedicine Cash-to-Debt vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, SHL Telemedicine's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where SHL Telemedicine's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHL Telemedicine (SHMLF) has a Cash-to-Debt of 1.93 as of Dec. 2025. This is 124% above median its historical median of 0.86. Over the past decade, SHL Telemedicine's Cash-to-Debt has ranged from 0.45 to 9.50. According to the industry distribution chart, SHL Telemedicine ranks #228 out of 663 companies in the Healthcare Providers & Services industry, placing it in the top 34.4%.
Is SHL Telemedicine's Cash-to-Debt too high?
SHL Telemedicine's current Cash-to-Debt of 1.93 is 124% above median its 10-year median of 0.86. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 9.50. The Healthcare Providers & Services industry median Cash-to-Debt is 0.77. SHL Telemedicine's value of 1.93 is 150.6% above this industry median. Based on the distribution chart, SHL Telemedicine ranks #228 out of 663 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, SHL Telemedicine has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does SHL Telemedicine's Cash-to-Debt compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, SHL Telemedicine ranks #228 out of 663 companies for Cash-to-Debt. This puts SHL Telemedicine in the upper half of its industry. The industry median Cash-to-Debt is 0.77. SHL Telemedicine's value of 1.93 is 150.6% above this benchmark. Historically, SHL Telemedicine's own Cash-to-Debt has ranged from 0.45 to 9.50 over the past decade. While the company's 10-year median is 0.86 vs. the industry median of 0.77, SHL Telemedicine has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.77, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SHL Telemedicine's current Cash-to-Debt of 1.93 is 150.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SHL Telemedicine's current Cash-to-Debt is 1.93, which is 124% above median its own 10-year median of 0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SHL Telemedicine stock overvalued right now?
SHL Telemedicine (SHMLF) has a current Cash-to-Debt of 1.93. The stock's GF Value™ is $11.86, compared to a current price of $4.84 — trading 59.2% below its estimated fair value. The current Cash-to-Debt is 1.93, which is 124% above median its 10-year median of 0.86 and 150.6% above the Healthcare Providers & Services industry median of 0.77. SHL Telemedicine's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For SHL Telemedicine (SHMLF), the current Cash-to-Debt is 1.93 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SHL Telemedicine (SHMLF) Overvalued in 2026?
Based on GuruFocus' analysis, SHL Telemedicine stock appears to be undervalued.
The current stock price of $4.84 is trading 59.2% below its estimated GF Value™ of $11.86.
Key valuation signals for SHMLF:
Cash-to-Debt: 1.93 (124% above median its 10-year median of 0.86)
GF Value™: $11.86 vs. price of $4.84 (59.2% below fair value)
Industry Position: 150.6% above the Healthcare Providers & Services median (#228 of 663)
No single metric tells the full story. See the SHMLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SHL Telemedicine Ltd develops and markets personal telemedicine solutions. The company consists of the transmission of medical data by an individual, from a remote location to a medical call center, through telecommunication networks. The company provides healthcare professional solutions to patients suffering from congestive heart failure, chronic obstructive pulmonary disease, and readmission solutions for reducing heart-related readmissions. In addition, consumer solutions include cardiac monitoring services. The company's geographical segments are Israel, Europe, and the rest of the world, out of which majority of revenue comes from Israel.
51GF Score
Get the complete analysis for SHMLF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHMLF has been successfully added to your 
